Diagnostic and Pharmaceutical News for You and Your Medical Practice

Size: px

Start display at page:

Download "Diagnostic and Pharmaceutical News for You and Your Medical Practice"

Annabel Rosa Clark
5 years ago
Views:

1 15MS3092 BioTherapeutics Q u a r t e r l y Diagnostic and Pharmaceutical News for You and Your Medical Practice Volume 20/Summer 2015 Illustration: Human Liver

2 BQ BioTherapeutics 2

3 BQ BioTherapeutics Q u a r t e r l y Volume 20/Summer 2015 Table of Contents 5 A Letter to Henry Schein s Valued Customers 6 MMWR: Increases in Hepatitis C Virus Infection Related to Injection Drug Use Among Persons Aged <30 years Kentucky, Tennessee, Virginia, and West Virginia, The ABCs of Hepatitis 13 New Drug Approvals 15 NIH Research Matters: Allergy Drug Treats Hepatitis C in Mice 18 NIH Research Matters: High-Resolution Imaging Technique May Advance Drug Design 20 National Institute of Mental Health: Depression in Children and Adolescents Fact Sheet 22 CDC Vital Signs: Hispanic Health 26 NIH: Colorectal Cancer Fact Sheet 30 MMWR Early Release: Melanoma Incidence and Mortality Trends and Projections United States, CDC VItal Signs: Preventing Melanoma 41 NIH: Prostate Cancer Fact Sheet The BioTherapeutics Journal is published four times a year by Henry Schein, Inc. Henry Schein s corporate headquarters are located at 135 Duryea Road, Melville, NY For journal sales information or to report corrections, BQJournal@henryschein.com or call Kim Crabtree at Note that although we attempt to ensure the currency of the information contained in this publication as of the publication date, new biotherapeutic developments occur continually and, therefore, may not be noted in this publication. Not responsible for typographical errors. 3 BQ BioTherapeutics

4 4 BQ BioTherapeutics

A Letter to Henry Schein s Valued Customers Summer has arrived and as 2015 gains speed, the BioTherapeutics journal strives to bring you the latest information on topics that are of interest to you,

5 A Letter to Henry Schein s Valued Customers Summer has arrived and as 2015 gains speed, the BioTherapeutics journal strives to bring you the latest information on topics that are of interest to you, the healthcare practitioner. The BioTherapeutics s goal is to provide our loyal customers current, relative information on the prevention, diagnosis, and treatment of disease. In this issue, we will be exploring several different topics including increases in Hepatitis C virus infection related to injection drug use, how high resolution imaging techniques may advance drug design, depression in children and adolescents, Hispanic health, colorectal cancer, melanoma incidence and mortality trends and projections, and prostate cancer. There are an estimated 3.2 million people with chronic Hepatitis C virus infection and 75-85% of newly infected persons develop chronic infection. On page 12, the article MMWR: Increases in Hepatitis C Virus Infection Related to Drug Use Among Persons Aged 30 Years Kentucky, Tennessee, Virginia, and West Virginia, discusses surveillance data, which showed a substantial increase of 364% in the number of cases of acute HCV infection from During , a total of 1,377 cases of acute HCV infection were reported to the CDC from these 4 states. There is currently no vaccine for Hepatitis C virus. About 1 in 6 people living in the US are Hispanic. VitalSigns: Hispanic Health on page 22 discusses how heart disease and cancer are the two leading causes of death, accounting for about 2 of 5 deaths. Hispanics are about 50% more likely to die from diabetes or liver diseases than whites. Hispanics in the US are on average nearly 15 years younger than whites, so steps Hispanics take now to prevent disease can go a long way towards a healthy future. Skin cancer is the most common form of cancer in the United States, and melanoma is responsible for the most skin cancer deaths with over 9,000 each year. MMWR Vital Signs: Melanoma Incidence and Mortality Trends and Projections United States, on page 30 discusses the growing treatment costs, incidences, and projections through The rate of new cases of melanoma doubled from We hope you find the topics featured in this volume informative. If you have suggestions for future topics, please forward these to BQJournal@henryschein.com and we will review your request. Sincerely, Kim Crabtree Director of Pharmaceuticals OUR Mission To provide health care professionals with a practical and relevant source of information regarding diagnostics, pharmaceuticals, and vaccines in a quick and easy-to-read publication that provides educational updates and insight to assist you in prevention, diagnosis, and treatment of disease. 5 BQ BioTherapeutics

6 BQ BioTherapeutics 6

7 7 BQ BioTherapeutics

8 BQ BioTherapeutics 8

9 9 BQ BioTherapeutics

10 Source: mm6417a2.htm BQ BioTherapeutics 10

11 11 BQ BioTherapeutics

12 Source: BQ BioTherapeutics 12

13 NEW DRUG APPROVALS May 27, 2015 Viberzi (eluxadoline) Tablets Treatment for: Irritable Bowel Syndrome Viberzi (eluxadoline) is a mu-opioid receptor agonist indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. Manufacturer: Actavis plc May 21, 2015 Stiolto Respimat (olodaterol and tiotropium) Inhalation Spray Treatment for: Chronic Obstructive Pulmonary Disease Stiolto Respimat (olodaterol and tiotropium bromide) is a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD). Manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc. May 18, 2015 Invega Trinza (paliperidone palmitate) Extended-Release Injectable Suspension Treatment for: Schizophrenia Invega Trinza (3-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia. Manufacturer: Janssen Pharmaceuticals, Inc. April 30, 2015 Tuzistra XR (chlorpheniramine polistirex and codeine polistirex) Extended Release Oral Suspension Treatment for: Cold Symptoms Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) is an extended-release opiate agonist antitussive and histamine-1 (H1) receptor antagonist combination indicated for the relief of cough and symptoms associated with upper respiratory allergies or the common cold. Manufacturer: Vernalis plc and Tris Pharma Inc. April 29, 2015 Kybella (deoxycholic acid) Injection - formerly ATX-101 Treatment for: Submental Fullness Kybella (deoxycholic acid) is a cytolytic drug indicated to improve the appearance of fullness associated with submental fat (double chin). Manufacturer: Kythera Biopharmaceuticals, Inc. March 24, 2015 Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV Vaccine) Injection Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Poliomyelitis Prophylaxis, Pertussis Prophylaxis Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) is a vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. Manufacturer: Sanofi Pasteur 13 BQ BioTherapeutics

14 BQ BioTherapeutics 14

15 15 BQ BioTherapeutics

Source: www.nih.gov/researchmatters/april2015/04202015hepatitis.

Henry Schein s DxRx Hotline is a single point of contact for your organization for answers to various types of questions related to diagnostics, pharmaceuticals, and vaccines.

16 Source: CLINICAL Make one call or to our diagnostics, pharmaceutical, and vaccine experts and let us do the research it s better than a PDR for point-of-care assistance. Henry Schein s DxRx Hotline is a single point of contact for your organization for answers to various types of questions related to diagnostics, pharmaceuticals, and vaccines. With a mission of helping practices diagnose, prevent, and treat disease, the DxRx team is available as a trustworthy and accessible source of information at your convenience. The DxRx team is available via phone, , and Live Chat, 8 am 6 pm, et. BENEFITS: Expedite diagnosis and treatment at the point of care Free, on-demand resource for immediate needs Easy-to-access and use resource One phone call to answer pharmaceutical, diagnostic, and vaccination questions Live support with no automation FEATURES: DxRx can answer questions related to: Latest updates on supply issues Indications and usage as provided on package inserts Brand-to-generic conversions CPT and J codes* CLIA product status Product storage requirements ACIP recommendations for vaccinations Flu vaccine and flu-related topics *For informational purposes only. Source: or Customer is responsible for verification of billing/coding in accordance with applicable specific circumstance. Contact Us: DxRxSolutions@henryschein.com Visit: BQ BioTherapeutics 16

17 17 BQ BioTherapeutics

18 Source: BQ BioTherapeutics 18

19 19 BQ BioTherapeutics

20 BQ BioTherapeutics 20

21 Source: 21 BQ BioTherapeutics

22 BQ BioTherapeutics 22

23 23 BQ BioTherapeutics

24 BQ BioTherapeutics 24

25 Source: 25 BQ BioTherapeutics

26 BQ BioTherapeutics 26

27 Source: 27 BQ BioTherapeutics

28 These services will help you contain costs and increase profitability. Rx PHARMACY DISCOUNT CARD* Save your patients hundreds of dollars on medication with our exclusive pharmaceuticals discount card. PHARMACY DISCOUNT CARD Rx BIN: Rx PCN: HT Member ID: Rx GROUP: USARX99999 Save up to 75% on all FDA-approved medications Use this card on brand and generic medications. You will not be turned down for pre-existing conditions. No pre-approval needed. This is not insurance. Call: Visit: *Henry Schein may receive a marketing fee from the vendor from products/services purchased BQ BioTherapeutics 28

29 29 BQ BioTherapeutics

30 BQ BioTherapeutics 30

31 31 BQ BioTherapeutics

32 BQ BioTherapeutics 32

33 33 BQ BioTherapeutics

34 BQ BioTherapeutics 34

35 Source: 35 BQ BioTherapeutics

Stocking 30 50 of your most commonly prescribed generic medications will cover approximately 80% of patient needs. Call: 1.877.523.7468 Visit: www.henryschein.

36 These services will support revenue generation and the expansion of services in your facility. In-Office Rx Dispensing Dispense prepackaged medications to improve patient health, lower costs and enhance revenue streams. Stocking of your most commonly prescribed generic medications will cover approximately 80% of patient needs. Call: Visit: sampling program A free and secure online service for Eligible* prescribers. Increase patient compliance: 30% of patients fill a Rx only when provided a sample, regardless of their age, income or gender** *Only eligible prescribers are able to enroll and order samples through the Henry Schein Rx Samples Service.Prescribers can check their eligibility by calling or visiting the website. **Source: Datamonitor Call: Visit: BQ BioTherapeutics 36

37 37 BQ BioTherapeutics

38 BQ BioTherapeutics 38

39 39 BQ BioTherapeutics

40 Source: BQ BioTherapeutics 40

41 41 BQ BioTherapeutics

42 Source: BQ BioTherapeutics 42

Are You Still Using Technology From The 1970s? Not Likely! So why aren t you recommending the NEW technology silver?

SilvrSTAT is a NEW type of silver that immediately and continuously kills harmful bacteria Water based no alcohol, alginate or sulfa. No known adverse events.

device insertion Protect Your Patients Against Community Acquired Infections Reimbursed as a hydrogel using HCPCS code A6248 SilvrSTAT (Rx) Antibacterial Wound Dressing Gel (685-0183)...1 oz.

43 Are You Still Using Technology From The 1970s? Not Likely! So why aren t you recommending the NEW technology silver? MRSA is one of the most troubling health care concerns causing over 94,000 hospitalization and 18,000 deaths per year SilvrSTAT* is the only multivalent silver FDA-indicated to inhibit MRSA! SilvrSTAT is a NEW type of silver that immediately and continuously kills harmful bacteria Water based no alcohol, alginate or sulfa. No known adverse events. SilvrSTAT is indicated for the management of skin tears, lacerations, abrasions, 1st and 2nd degree burns, wounds such as stasis ulcers, pressure ulcers, diabetic ulcers, surgical incision sites, device insertion Protect Your Patients Against Community Acquired Infections Reimbursed as a hydrogel using HCPCS code A6248 SilvrSTAT (Rx) Antibacterial Wound Dressing Gel ( )...1 oz. BEST VALUE Save 30% vs the 1 oz. size! ( )...3 oz. *Caution: Federal law restricts the sale of this device by, or on the order of, a licensed health care practitioner. For informational purposes only. Source: ABL Medical, LLC. Customer is responsible for verification of billing/coding in accordance with applicable specific circumstances. EXCLUSIVE! NEW! Acnizil is formulated with a proprietary and patented nanoparticulate silver clinically proven to kill the Propionibacterium acnes (P. acnes) bacteria. Acnizil does not require a prescription & can be used on mild, moderate & severe acne. ( ) Acnizil 1.5 oz. Tube (12/Case) Acne is very common during pregnancy but there are very few safe treatment options as many prescription and over the counter products should not be taken while pregnant. Acnizil is a great alternative to antibiotics. It is a safe and effective way for patients to manage acne while they are pregnant. Michael Swor, MD, OB/GYN For more information visit: 43 BQ BioTherapeutics

Call: 1-800-P-SCHEIN (1-800-772-4346) 8am 8:30pm (et) Fax: 1-800-329-9109 24 Hours www.henryschein.com/medical 2015 Henry Schein, Inc.

44 Call: P-SCHEIN ( ) 8am 8:30pm (et) Fax: Hours Henry Schein, Inc. No copying without permission. Not responsible for typographical errors. 15MS3092 Call your Henry Schein Sales Consultant for additional details!

Diagnostic and Pharmaceutical News for You and Your Medical Practice

16MS5075 BioTherapeutics Q u a r t e r l y Diagnostic and Pharmaceutical News for You and Your Medical Practice Volume 22/Winter 2016 2 016 Welcome to the Worry-Free Guarantee Flu Vaccine Program Celebrating